Leading the Exploration
of the Vitanome
VitaPath Genetics, Inc. has developed a platform for genomic-based tests that determine an individual’s need for vitamin therapy in medically actionable conditions. Using its platform, VitaPath develops specific assays that test for the risk of vitamin-remediable diseases and that can help manage the use of $30 billion of supplements purchased in the U.S. each year. The first test developed by VitaPath measures genetic risk factors associated with spina bifida to identify women who would benefit from prescription-strength folic acid supplementation.
Its mission is to explore the genetic variation associated with vitamin-responsive genes and to understand their influence on key metabolic pathways and processes. With this knowledge, VitaPath can develop genetic tests to identify individuals whose vitamin genetics put them at increased risk for serious medical conditions.
Facts & Stats
- Spina Bifida affects more than 3,000 births a year; it is the most common debilitating birth defect.
- Spina Bifida can be prevented if at-risk women are identified and begin folic acid therapy prior to conception.
- High dose folic acid is available only by prescription; it cannot be given to all women regardless of risk.
- VitaPath was founded in 2009.
